{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:10:14Z","timestamp":1788765014057,"version":"build-2803163510"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12015-026-11184-8","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:59:50Z","timestamp":1782961190000},"page":"3033-3055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming Immunological Barriers in MSC-Derived Insulin-Producing Cells through CRISPR-Based Hypoimmunogenic Engineering and Translational Perspectives for Type 1 Diabetes"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0387-0103","authenticated-orcid":false,"given":"Zahid","family":"Yaseen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0451-2890","authenticated-orcid":false,"given":"Mothilal","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"11184_CR1","doi-asserted-by":"publisher","unstructured":"Altabas, V., & Bulum, T. (2024). Current Challenges in Pancreas and Islet Transplantation: A Scoping Review, Biomed, 12, 2853. https:\/\/doi.org\/10.3390\/BIOMEDICINES12122853","DOI":"10.3390\/BIOMEDICINES12122853"},{"key":"11184_CR2","doi-asserted-by":"publisher","unstructured":"Addissouky, T. A., Ali, M. M. A., El, I. E. T., Sayed, & Wang, Y. (2024 481). Type 1 diabetes mellitus: retrospect and prospect. Bulletin National Research Century, 48, 1\u201315. https:\/\/doi.org\/10.1186\/S42269-024-01197-Z","DOI":"10.1186\/S42269-024-01197-Z"},{"key":"11184_CR3","doi-asserted-by":"publisher","unstructured":"Yaseen, Z., Nandave, M., & Sharma, L. (Mar. 2025). Anti-diabetic Biologicals: Exploring the Role of Different Analytical Techniques. Critical Reviews In Analytical Chemistry, 1\u201322. https:\/\/doi.org\/10.1080\/10408347.2025.2472793","DOI":"10.1080\/10408347.2025.2472793"},{"key":"11184_CR4","doi-asserted-by":"publisher","unstructured":"Bharambe, S. B., & Jawarkar, S. (2024). Lantidra: Cell Therapy for Treatment of Type 1 Diabetes Mellitus, Asian Journal of Pharmaceutical Research, 14(3), 331\u2013335. https:\/\/doi.org\/10.52711\/2231-5691.2024.00052","DOI":"10.52711\/2231-5691.2024.00052"},{"key":"11184_CR5","doi-asserted-by":"publisher","unstructured":"Kondo, Y., Toyoda, T., Inagaki, N., & Osafune, K. (Mar. 2017). iPSC technology-based regenerative therapy for diabetes. Journal of diabetes investigation, 9(2), 234\u2013243. https:\/\/doi.org\/10.1111\/JDI.12702","DOI":"10.1111\/JDI.12702"},{"key":"11184_CR6","doi-asserted-by":"publisher","unstructured":"Hogrebe, N. J., Ishahak, M., & Millman, J. R. (May 2023). Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. Cell Stem Cell, 30(5), 530\u2013548. https:\/\/doi.org\/10.1016\/J.STEM.2023.04.002","DOI":"10.1016\/J.STEM.2023.04.002"},{"key":"11184_CR7","doi-asserted-by":"publisher","unstructured":"Wang, C., Wu, Y., & Jiang, J. (Dec. 2025). The role and mechanism of mesenchymal stem cells in immunomodulation of type 1 diabetes mellitus and its complications: recent research progress and challenges: a review. Stem Cell Research & Therapy, 16(1). https:\/\/doi.org\/10.1186\/S13287-025-04431-1","DOI":"10.1186\/S13287-025-04431-1"},{"issue":"6","key":"11184_CR8","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/S12015-020-10036-3","volume":"16","author":"MA Ghoneim","year":"2020","unstructured":"Ghoneim, M A., Refaie, A. F., Elbassiouny, B. L., Gabr, M. M., & Zakaria, M. M. (2020). From Mesenchymal Stromal\/Stem Cells to Insulin-Producing Cells: Progress and Challenges. Stem Cell Rev Reports, 16(6), 1156\u20131172. https:\/\/doi.org\/10.1007\/S12015-020-10036-3.","journal-title":"Stem Cell Rev Reports"},{"issue":"2","key":"11184_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.30476\/IJMS.2024.101162.3378","volume":"50","author":"S Mohammadian","year":"2025","unstructured":"Mohammadian, S., Hosseni, S. J., Dehbashi, F. N., & Dayer, D. (2025). The Insulin-Producing Cells Generated from Rat Adipose Tissue Mesenchymal Stem Cells via Pdx1 Overexpression Activate an Immune Response both in Vitro and in Vivo. Iran J Med Sci, 50(2), 112. https:\/\/doi.org\/10.30476\/IJMS.2024.101162.3378","journal-title":"Iran J Med Sci"},{"key":"11184_CR10","doi-asserted-by":"publisher","unstructured":"Mohammadi, N., et al. (Sep. 2020). Mouse bone marrow-derived mesenchymal stem cells acquire immunogenicity concurrent with differentiation to insulin-producing cells. Immunobiology, 225(5). https:\/\/doi.org\/10.1016\/j.imbio.2020.151994","DOI":"10.1016\/j.imbio.2020.151994"},{"key":"11184_CR11","doi-asserted-by":"publisher","unstructured":"Meshitsuka, S., Ninomiya, R., Nagamura-Inoue, T., Okada, T., Futami, M., & Tojo, A. (2022). CRISPR\/Cas9 and AAV mediated insertion of \u03b22 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy. Regenerative therapy, 21, 442\u2013452. https:\/\/doi.org\/10.1016\/j.reth.2022.09.009","DOI":"10.1016\/j.reth.2022.09.009"},{"key":"11184_CR12","doi-asserted-by":"publisher","unstructured":"Ghoneim, M. A., et al. (Dec. 2022). Transplantation of insulin-producing cells derived from human mesenchymal stromal\/stem cells into diabetic humanized mice. Stem Cell Research & Therapy, 13(1). https:\/\/doi.org\/10.1186\/S13287-022-03048-Y","DOI":"10.1186\/S13287-022-03048-Y"},{"key":"11184_CR13","doi-asserted-by":"publisher","unstructured":"Sano, H., & Imagawa, A. (2020). Pancreatic \u03b2-cells express major histocompatibility complex class II: Do diabetic \u03b2-cells have the capacity of antigen-presenting cells. Journal of diabetes investigation, 11(2), 281\u2013283. https:\/\/doi.org\/10.1111\/JDI.13155","DOI":"10.1111\/JDI.13155"},{"key":"11184_CR14","doi-asserted-by":"publisher","unstructured":"Morran, M. P., Vonberg, A., Khadra, A., & Pietropaolo, M. (Apr. 2015). Immunogenetics of type 1 diabetes mellitus. Molecular Aspects Of Medicine, 42, 42\u201360. https:\/\/doi.org\/10.1016\/j.mam.2014.12.004","DOI":"10.1016\/j.mam.2014.12.004"},{"key":"11184_CR15","doi-asserted-by":"publisher","unstructured":"Telang, G., Mishra, S., Sureshbabu, A., Chiloo, S., Joshi, S., & Thyagarajan, S. (Jun. 2025). HLA Class I and II genes: A key factor for type one diabetes susceptibility. Gene Reports, 39, 102183. https:\/\/doi.org\/10.1016\/J.GENREP.2025.102183","DOI":"10.1016\/J.GENREP.2025.102183"},{"key":"11184_CR16","doi-asserted-by":"publisher","unstructured":"Alves Abrantes, J. J. P., et al. (May 2024). Viruses as a potential environmental trigger of type 1 diabetes mellitus (Review). Biomed Reports, 20(5), 1\u201314. https:\/\/doi.org\/10.3892\/BR.2024.1770\/HTML","DOI":"10.3892\/BR.2024.1770\/HTML"},{"key":"11184_CR17","doi-asserted-by":"publisher","unstructured":"Nekoua, M. P., Alidjinou, E. K., & Hober, D. (2022). Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nature reviews. Endocrinology, 18(8), 503\u2013516. https:\/\/doi.org\/10.1038\/S41574-022-00688-1","DOI":"10.1038\/S41574-022-00688-1"},{"key":"11184_CR18","doi-asserted-by":"publisher","unstructured":"Le\u015bniak, C. (2026). Intestinal Microbiota in Diabetes\u2014Does the Pathomechanism and Diversity Depend on the Type of Diabetes and Coexisting Metabolic Disorders? Journal of Clinical Medicine, 15(7). https:\/\/doi.org\/10.3390\/JCM15072604","DOI":"10.3390\/JCM15072604"},{"key":"11184_CR19","doi-asserted-by":"publisher","unstructured":"Quinn, L. M., Wong, F. S., & Narendran, P. (Oct. 2021). Environmental Determinants of Type 1 Diabetes: From Association to Proving Causality. Frontiers In Immunology, 12, 737964. https:\/\/doi.org\/10.3389\/FIMMU.2021.737964\/FULL","DOI":"10.3389\/FIMMU.2021.737964\/FULL"},{"key":"11184_CR20","doi-asserted-by":"publisher","unstructured":"Sahin, G. S., Lee, H., & Engin, F. (Dec. 2021). An accomplice more than a mere victim: The impact of \u03b2-cell ER stress on type 1 diabetes pathogenesis. Molecular Metabolism, 54, 101365. https:\/\/doi.org\/10.1016\/J.MOLMET.2021.101365","DOI":"10.1016\/J.MOLMET.2021.101365"},{"key":"11184_CR21","doi-asserted-by":"publisher","unstructured":"Zajec, A. (2022). Apr., Pathogenesis of Type 1 Diabetes: Established Facts and New Insights, Genes (Basel), 13(4), 706. https:\/\/doi.org\/10.3390\/GENES13040706","DOI":"10.3390\/GENES13040706"},{"key":"11184_CR22","doi-asserted-by":"publisher","unstructured":"Fan, X. L., Zhang, Y., Li, X., & Fu, Q. L. (2020 7714). Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy, Cellular and Molecular Life Sciences 77(14), 2771\u20132794. https:\/\/doi.org\/10.1007\/S00018-020-03454-6","DOI":"10.1007\/S00018-020-03454-6"},{"key":"11184_CR23","doi-asserted-by":"publisher","unstructured":"Oh, J. Y. (2022). Sep., MHC Class I Enables MSCs to Evade NK-Cell\u2013Mediated Cytotoxicity and Exert Immunosuppressive Activity, Stem Cells, 40(9), 870\u2013882. https:\/\/doi.org\/10.1093\/STMCLS\/SXAC043","DOI":"10.1093\/STMCLS\/SXAC043"},{"key":"11184_CR24","doi-asserted-by":"publisher","unstructured":"Ghoneim, M. A., Gabr, M. M., El-Halawani, S. M., & Refaie, A. F. (2024 151). Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration, Stem cell research & therapy, 15(1), 1\u201313. https:\/\/doi.org\/10.1186\/S13287-024-03636-0","DOI":"10.1186\/S13287-024-03636-0"},{"key":"11184_CR25","doi-asserted-by":"publisher","unstructured":"Thanaskody, K., Jusop, A. S., Tye, G. J., Wan Kamarul Zaman, W. S., Dass, S. A., & Nordin, F. (Nov. 2022). MSCs vs. iPSCs: Potential in therapeutic applications. Frontiers in Cell and Developmental Biology, 10, 1005926. https:\/\/doi.org\/10.3389\/FCELL.2022.1005926","DOI":"10.3389\/FCELL.2022.1005926"},{"key":"11184_CR26","doi-asserted-by":"publisher","unstructured":"Han, L. (2022). Feb., Distinctive Clinical and Pathologic Features of Immature Teratomas Arising from Induced Pluripotent Stem Cell-Derived Beta Cell Injection in a Diabetes Patient., Stem cells and development, 31(5\u20136), 97\u2013101. https:\/\/doi.org\/10.1089\/scd.2021.0255","DOI":"10.1089\/scd.2021.0255"},{"key":"11184_CR27","doi-asserted-by":"publisher","unstructured":"Sui, L., et al. (Mar. 2021). Reduced replication fork speed promotes pancreatic endocrine differentiation and controls graft size. JCI Insight, 6(5), e141553. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.141553","DOI":"10.1172\/JCI.INSIGHT.141553"},{"key":"11184_CR28","doi-asserted-by":"publisher","unstructured":"Kirkeby, A., Main, H., & Carpenter, M. (Jan. 2025). Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell, 32(1), 10\u201337. https:\/\/doi.org\/10.1016\/j.stem.2024.12.005","DOI":"10.1016\/j.stem.2024.12.005"},{"key":"11184_CR29","doi-asserted-by":"publisher","unstructured":"Shi, M., Liu, Z. W., & Wang, F. S. (Apr. 2011). Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clinical And Experimental Immunology, 164(1), 1. https:\/\/doi.org\/10.1111\/J.1365-2249.2011.04327.X","DOI":"10.1111\/J.1365-2249.2011.04327.X"},{"key":"11184_CR30","doi-asserted-by":"publisher","unstructured":"Khosravi, M., et al. (Oct. 2018). Induction of CD4\u2009+\u2009CD25\u2009+\u2009FOXP3\u2009+\u2009regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation. Stem Cell Research & Therapy, 9(1), 1\u201318. https:\/\/doi.org\/10.1186\/S13287-018-0991-1\/FIGURES\/7","DOI":"10.1186\/S13287-018-0991-1\/FIGURES\/7"},{"key":"11184_CR31","doi-asserted-by":"publisher","unstructured":"Weiss, A. R. R., & Dahlke, M. H. (2019). Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs, Frontiers in immunology, 10, 1191. https:\/\/doi.org\/10.3389\/FIMMU.2019.01191","DOI":"10.3389\/FIMMU.2019.01191"},{"key":"11184_CR32","doi-asserted-by":"publisher","unstructured":"Refaie, A. F., et al. (Jun. 2021). From Mesenchymal Stromal\/Stem Cells to Insulin-Producing Cells: Immunological Considerations. Frontiers In Immunology, 12, 690623. https:\/\/doi.org\/10.3389\/FIMMU.2021.690623\/XML","DOI":"10.3389\/FIMMU.2021.690623\/XML"},{"key":"11184_CR33","doi-asserted-by":"publisher","unstructured":"Chen, W., Lv, L., Chen, N., & Cui, E. (Jun. 2023). Immunogenicity of mesenchymal stromal\/stem cells. Scandinavian Journal Of Immunology, 97(6), e13267. https:\/\/doi.org\/10.1111\/SJI.13267","DOI":"10.1111\/SJI.13267"},{"key":"11184_CR34","doi-asserted-by":"publisher","first-page":"9824698","DOI":"10.1155\/2017\/9824698","volume":"2017","author":"RL Oliveira","year":"2017","unstructured":"Oliveira, R. L., Chagastelles, P. C., Sesterheim, P., & Pranke, P. (2017). In Vivo Immunogenic Response to Allogeneic Mesenchymal Stem Cells and the Role of Preactivated Mesenchymal Stem Cells Cotransplanted with Allogeneic Islets. Stem Cells Int, 2017, 9824698. https:\/\/doi.org\/10.1155\/2017\/9824698","journal-title":"Stem Cells Int"},{"key":"11184_CR35","doi-asserted-by":"publisher","unstructured":"Schu, S. (2094). Immunogenicity of allogeneic mesenchymal stem cells, Journal of cellular and molecular medicine, 16(9). https:\/\/doi.org\/10.1111\/J.1582-4934.2011.01509.X","DOI":"10.1111\/J.1582-4934.2011.01509.X"},{"key":"11184_CR36","doi-asserted-by":"publisher","unstructured":"Pellegrini, S., Zamarian, V., & Sordi, V. (Aug. 2022). Strategies to Improve the Safety of iPSC-Derived \u03b2 Cells for \u03b2 Cell Replacement in Diabetes. Transplant International, 35, 10575. https:\/\/doi.org\/10.3389\/TI.2022.10575\/FULL","DOI":"10.3389\/TI.2022.10575\/FULL"},{"key":"11184_CR37","doi-asserted-by":"publisher","unstructured":"Redman, M., King, A., Watson, C., & King, D. (Aug. 2016). What is CRISPR\/Cas9? Arch Dis Child Educ Pract Ed, 101(4), 213. https:\/\/doi.org\/10.1136\/ARCHDISCHILD-2016-310459","DOI":"10.1136\/ARCHDISCHILD-2016-310459"},{"key":"11184_CR38","doi-asserted-by":"publisher","unstructured":"Parent, A. V., et al. (Aug. 2021). Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Cell Rep, 36(7). https:\/\/doi.org\/10.1016\/J.CELREP.2021.109538","DOI":"10.1016\/J.CELREP.2021.109538"},{"key":"11184_CR39","doi-asserted-by":"publisher","unstructured":"Dashti, M., Mohammaddust Sarab, M., Shad, F., & Dehnavi, S. (Dec. 2025). CRISPR-mediated engineering of mesenchymal stromal\/stem cells: a summary of recent progress in immunological applications for regenerative medicine and cancer therapy. Stem Cell Research & Therapy, 16(1), 592. https:\/\/doi.org\/10.1186\/S13287-025-04723-6","DOI":"10.1186\/S13287-025-04723-6"},{"key":"11184_CR40","doi-asserted-by":"publisher","unstructured":"Kim, J., et al. (Mar. 2025). Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockout. Experimental & Molecular Medicine, 57(3), 686. https:\/\/doi.org\/10.1038\/S12276-025-01422-3","DOI":"10.1038\/S12276-025-01422-3"},{"key":"11184_CR41","doi-asserted-by":"publisher","unstructured":"Zha, S., Tay, J. C. K., Zhu, S., Li, Z., Du, Z., & Wang, S. (2020). Generation of Mesenchymal Stromal Cells with Low Immunogenicity from Human PBMC-Derived \u03b22 Microglobulin Knockout Induced Pluripotent Stem Cells. Cell Transplantation, 29. https:\/\/doi.org\/10.1177\/0963689720965529\/SUPPL_FILE\/GENERATION_OF_MESENCHYMAL_STROMAL_CELLS_WITH_LOW_IMMUNOGENICITY_FROM_HUMAN_PBMC.PDF","DOI":"10.1177\/0963689720965529\/SUPPL_FILE\/GENERATION_OF_MESENCHYMAL_STROMAL_CELLS_WITH_LOW_IMMUNOGENICITY_FROM_HUMAN_PBMC.PDF"},{"key":"11184_CR42","doi-asserted-by":"publisher","unstructured":"Kwon, D., et al. (Aug. 2020). Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells. Stem Cell Rev Reports, 16(4), 792\u2013808. https:\/\/doi.org\/10.1007\/S12015-020-09990-9\/METRICS","DOI":"10.1007\/S12015-020-09990-9\/METRICS"},{"key":"11184_CR43","doi-asserted-by":"publisher","first-page":"1389358","DOI":"10.3389\/fimmu.2024.1389358","volume":"15","author":"E Ferron","year":"2024","unstructured":"Ferron, E., et al. (2024). Multifactorial determinants of NK cell repertoire organization: insights into age, sex, KIR genotype, HLA typing, and CMV influence. Frontiers In Immunology, 15, 1389358. https:\/\/doi.org\/10.3389\/fimmu.2024.1389358","journal-title":"Frontiers In Immunology"},{"issue":"1","key":"11184_CR44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7150\/IJBS.64640","volume":"18","author":"D Zheng","year":"2022","unstructured":"Zheng, D., et al. (2022). Engineering of human mesenchymal stem cells resistant to multiple natural killer subtypes. International Journal Of Biological Sciences, 18(1), 426. https:\/\/doi.org\/10.7150\/IJBS.64640","journal-title":"International Journal Of Biological Sciences"},{"key":"11184_CR45","doi-asserted-by":"publisher","unstructured":"Gornalusse, G. G., et al. (Aug. 2017). HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nature Biotechnology, 35, 765. https:\/\/doi.org\/10.1038\/nbt.3860","DOI":"10.1038\/nbt.3860"},{"key":"11184_CR46","doi-asserted-by":"publisher","unstructured":"Cocker, A. T. H., Liu, F., Djaoud, Z., Guethlein, L. A., & Parham, P. (Sep. 2022). CD56-negative NK cells: Frequency in peripheral blood, expansion during HIV-1 infection, functional capacity, and KIR expression. Frontiers In Immunology, 13, 992723. https:\/\/doi.org\/10.3389\/fimmu.2022.992723","DOI":"10.3389\/fimmu.2022.992723"},{"key":"11184_CR47","doi-asserted-by":"publisher","unstructured":"Hiura, S., et al. (Sep. 2025). Selective agonists of KIR and NKG2A to evade missing self response of natural killer cells. Sci Reports, 15(1), 33550. https:\/\/doi.org\/10.1038\/s41598-025-18394-z","DOI":"10.1038\/s41598-025-18394-z"},{"key":"11184_CR48","doi-asserted-by":"publisher","unstructured":"Chimienti, R., et al. (Sep. 2022). Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I\u2013\/\u2013 iPSCs for \u03b2 cell replacement. Cell Rep, 40(13). https:\/\/doi.org\/10.1016\/j.celrep.2022.111423","DOI":"10.1016\/j.celrep.2022.111423"},{"issue":"3","key":"11184_CR49","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/S41587-023-01784-X","volume":"42","author":"X Hu","year":"2024","unstructured":"Hu, X., & Mar. (2024). Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nature Biotechnology, 42(3), 413\u2013423. https:\/\/doi.org\/10.1038\/S41587-023-01784-X","journal-title":"Nature Biotechnology"},{"key":"11184_CR50","doi-asserted-by":"publisher","unstructured":"Carlsson, P. O., et al. (Sep. 2025). Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression. New England Journal Of Medicine, 393(9). https:\/\/doi.org\/10.1056\/NEJMOA2503822","DOI":"10.1056\/NEJMOA2503822"},{"key":"11184_CR51","doi-asserted-by":"publisher","unstructured":"Asenjo, J., et al. (Nov. 2024). NKG2C Sequence Polymorphism Modulates the Expansion of Adaptive NK Cells in Response to Human CMV. Hla, 104(5), e15764. https:\/\/doi.org\/10.1111\/tan.15764","DOI":"10.1111\/tan.15764"},{"key":"11184_CR52","doi-asserted-by":"publisher","unstructured":"Orbelyan, G. A., et al. (Jul. 2014). Human NKG2E is expressed and forms an intracytoplasmic complex with CD94 and DAP12. The Journal Of Immunology, 193(2), 610. https:\/\/doi.org\/10.4049\/jimmunol.1400556","DOI":"10.4049\/jimmunol.1400556"},{"key":"11184_CR53","doi-asserted-by":"publisher","first-page":"1143157","DOI":"10.3389\/FBIOE.2023.1143157\/FULL","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR\/Cas9 gene editing. Frontiers In Bioengineering And Biotechnology, 11, 1143157. https:\/\/doi.org\/10.3389\/FBIOE.2023.1143157\/FULL","journal-title":"Frontiers In Bioengineering And Biotechnology"},{"key":"11184_CR54","doi-asserted-by":"publisher","unstructured":"Lopes, R., & Prasad, M. K. (Jan. 2023). Beyond the promise: evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics. Frontiers In Bioengineering And Biotechnology, 11, 1339189. https:\/\/doi.org\/10.3389\/FBIOE.2023.1339189\/FULL","DOI":"10.3389\/FBIOE.2023.1339189\/FULL"},{"key":"11184_CR55","doi-asserted-by":"publisher","unstructured":"Jiang, L., et al. (Jan. 2021). CRISPR\/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies. Cancer Research, 82(1), 36. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1692","DOI":"10.1158\/0008-5472.CAN-21-1692"},{"key":"11184_CR56","doi-asserted-by":"publisher","unstructured":"Tran, N. T., et al. (Jun. 2022). Precise CRISPR-Cas-mediated gene repair with minimal off-target and unintended on-target mutations in human hematopoietic stem cells. Science Advances, 8(22). https:\/\/doi.org\/10.1126\/SCIADV.ABM9106","DOI":"10.1126\/SCIADV.ABM9106"},{"key":"11184_CR57","doi-asserted-by":"publisher","unstructured":"Yang, H. (2020). Sep., Methods Favoring Homology-Directed Repair Choice in Response to CRISPR\/Cas9 Induced-Double Strand Breaks, International Journal of Molecular Sciences, 21(18), 6461. https:\/\/doi.org\/10.3390\/IJMS21186461","DOI":"10.3390\/IJMS21186461"},{"key":"11184_CR58","doi-asserted-by":"publisher","unstructured":"Yoshimi, K. (2020). Feb., Combi-CRISPR: combination of NHEJ and HDR provides efficient and precise plasmid-based knock-ins in mice and rats, Human Genetics, 140(2), 277. https:\/\/doi.org\/10.1007\/S00439-020-02198-4","DOI":"10.1007\/S00439-020-02198-4"},{"key":"11184_CR59","doi-asserted-by":"publisher","unstructured":"Inen, J., Han, C. M., Farrel, D. M., Bilousova, G., & Kogut, I. (Nov. 2024). CIRCLE-seq for interrogation of off-target gene editing. Journal Of Visualized Experiments: Jove. https:\/\/doi.org\/10.3791\/67069","DOI":"10.3791\/67069"},{"key":"11184_CR60","doi-asserted-by":"publisher","unstructured":"Tsai, S. Q., Nguyen, N. T., Malagon-Lopez, J., Topkar, V. V., Aryee, M. J., & Joung, J. K. (May 2017). CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nature Methods, 14(6), 607. https:\/\/doi.org\/10.1038\/NMETH.4278","DOI":"10.1038\/NMETH.4278"},{"key":"11184_CR61","doi-asserted-by":"publisher","unstructured":"Wienert, B., Wyman, S. K., Yeh, C. D., Conklin, B. R., & Corn, J. E. (May 2020). CRISPR off-target detection with DISCOVER-Seq. Nature Protocols, 15(5), 1775. https:\/\/doi.org\/10.1038\/S41596-020-0309-5","DOI":"10.1038\/S41596-020-0309-5"},{"key":"11184_CR62","doi-asserted-by":"publisher","unstructured":"Tao, J., Bauer, D. E., & Chiarle, R. (2023 141). Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. Nature communications, 14(1), 212. https:\/\/doi.org\/10.1038\/s41467-023-35886-6","DOI":"10.1038\/s41467-023-35886-6"},{"key":"11184_CR63","doi-asserted-by":"publisher","unstructured":"Qiao, Y., Agboola, O. S., Hu, X., Wu, Y., & Lei, L. (Dec. 2020). Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine. Stem Cell Rev Reports, 16(6), 1049. https:\/\/doi.org\/10.1007\/S12015-020-10042-5","DOI":"10.1007\/S12015-020-10042-5"},{"key":"11184_CR64","doi-asserted-by":"publisher","first-page":"1403395","DOI":"10.3389\/FGEED.2024.1403395\/FULL","volume":"6","author":"HR Frederiksen","year":"2024","unstructured":"Frederiksen, H. R., et al. (2024). CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice. Front Genome Ed, 6, 1403395. https:\/\/doi.org\/10.3389\/FGEED.2024.1403395\/FULL","journal-title":"Front Genome Ed"},{"key":"11184_CR65","doi-asserted-by":"publisher","unstructured":"Gleeson, T. A. (2024). Mar., The NLRP3 inflammasome is essential for IL-18 production in a murine model of macrophage activation syndrome. bioRxiv. https:\/\/doi.org\/10.1101\/2024.02.27.582284","DOI":"10.1101\/2024.02.27.582284"},{"key":"11184_CR66","doi-asserted-by":"publisher","unstructured":"Lee, J., et al. (Oct. 2020). Abrogation of HLA surface expression using CRISPR\/Cas9 genome editing: a step toward universal T cell therapy. Scientific reports, 10(1), 17753. https:\/\/doi.org\/10.1038\/s41598-020-74772-9","DOI":"10.1038\/s41598-020-74772-9"},{"key":"11184_CR67","doi-asserted-by":"publisher","unstructured":"McCallion, O., et al. (Dec. 2025). HLA matching or CRISPR editing of HLA class I\/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model. Nature Communications, 16(1), 9090. https:\/\/doi.org\/10.1038\/S41467-025-64945-3","DOI":"10.1038\/S41467-025-64945-3"},{"issue":"6","key":"11184_CR68","doi-asserted-by":"publisher","first-page":"e1286","DOI":"10.1002\/CTI2.1286","volume":"10","author":"LO Afolabi","year":"2021","unstructured":"Afolabi, L. O., et al. (2021). Exploiting the CRISPR-Cas9 gene\u2010editing system for human cancers and immunotherapy. Clin Transl Immunol, 10(6), e1286. https:\/\/doi.org\/10.1002\/CTI2.1286","journal-title":"Clin Transl Immunol"},{"key":"11184_CR69","doi-asserted-by":"publisher","unstructured":"Karpov, D. S., et al. (Dec. 2023). Challenges of CRISPR\/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a \u2018Trojan Horse\u2019. International Journal Of Molecular Sciences, 24(24), 17320. https:\/\/doi.org\/10.3390\/IJMS242417320","DOI":"10.3390\/IJMS242417320"},{"key":"11184_CR70","doi-asserted-by":"publisher","unstructured":"Koishybayeva, D., Amirashov, A., Balmagambetova, S., Mussin, N. M., & Tamadon, A. (Oct. 2025). Mesenchymal stem cell therapy for diabetes: An umbrella review. Tissue And Cell, 96, 103043. https:\/\/doi.org\/10.1016\/J.TICE.2025.103043","DOI":"10.1016\/J.TICE.2025.103043"},{"key":"11184_CR71","doi-asserted-by":"publisher","unstructured":"Zarei, M. (Dec. 2025). Mesenchymal stem cell therapy for type 2 diabetes: mechanisms, clinical evidence, and future directions. Molecular Biology Reports, 52(1). https:\/\/doi.org\/10.1007\/S11033-025-11133-7","DOI":"10.1007\/S11033-025-11133-7"},{"key":"11184_CR72","doi-asserted-by":"publisher","unstructured":"He, J. (2021). Mar., Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data. PloS one, 16(3), e0247662. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0247662","DOI":"10.1371\/JOURNAL.PONE.0247662"},{"key":"11184_CR73","doi-asserted-by":"publisher","unstructured":"Ishida, N., Ishiyama, K., Saeki, Y., Tanaka, Y., & Ohdan, H. (Oct. 2019). Cotransplantation of preactivated mesenchymal stem cells improves intraportal engraftment of islets by inhibiting liver natural killer cells in mice. American Journal Of Transplantation, 19(10), 2732\u20132745. https:\/\/doi.org\/10.1111\/AJT.15347\/ATTACHMENT\/3F10AF51-6B56-4DB7-920E-FE6F7644FADB\/MMC1-SUP1-FIGS1-S6.PDF","DOI":"10.1111\/AJT.15347\/ATTACHMENT\/3F10AF51-6B56-4DB7-920E-FE6F7644FADB\/MMC1-SUP1-FIGS1-S6.PDF"},{"key":"11184_CR74","doi-asserted-by":"publisher","unstructured":"Wang, S., et al. (Oct. 2024). Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell, 187(22), 6152\u20136164. https:\/\/doi.org\/10.1016\/j.cell.2024.09.004","DOI":"10.1016\/j.cell.2024.09.004"},{"key":"11184_CR75","unstructured":"Chinese Clinical Trial Register (ChiCTR) (accessed Jan. 27, 2026). - The world health organization international clinical trials registered organization registered platform. https:\/\/www.chictr.org.cn\/showprojEN.html?proj=192835"},{"key":"11184_CR76","unstructured":"Study Details (2026). | NCT06951074 | Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06951074?cond=NCT06951074&rank=1 (accessed Jan. 27."},{"key":"11184_CR77","doi-asserted-by":"publisher","unstructured":"Izadi, M., et al. (Dec. 2022). Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I\/II randomized placebo-controlled clinical trial. Stem Cell Research & Therapy, 13(1). https:\/\/doi.org\/10.1186\/S13287-022-02941-W","DOI":"10.1186\/S13287-022-02941-W"},{"key":"11184_CR78","unstructured":"No Study (2026). Results Posted | NCT04078308 | Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04078308?cond=NCT04078308&rank=1&tab=results (accessed Jan. 27."},{"key":"11184_CR79","unstructured":"Study Details (2026). | NCT06407297 | UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06407297?cond=NCT06407297&rank=1 (accessed Jan. 27."},{"key":"11184_CR80","doi-asserted-by":"publisher","unstructured":"Carlsson, P. O., Espes, D., Sisay, S., Davies, L. C., Smith, C. I. E., & Svahn, M. G. (2023). Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I\/II randomised double-blind placebo-controlled trial, Diabetologia, vol. 66, no. 8, pp. 1431\u20131441, Aug. https:\/\/doi.org\/10.1007\/S00125-023-05934-3","DOI":"10.1007\/S00125-023-05934-3"},{"key":"11184_CR81","unstructured":"Study Details (2026). | NCT03406585 | Wharton\u00b4s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03406585?cond=NCT03406585&rank=1 (accessed Jan. 27."},{"key":"11184_CR82","unstructured":"Study Details (2026). | NCT03973827 | Wharton\u00b4s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03973827?cond=NCT03973827&rank=1 (accessed Jan. 27."},{"key":"11184_CR83","unstructured":"Study Details (2026). | NCT04061746 | Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04061746?cond=NCT04061746&rank=1 (accessed Jan. 27."},{"key":"11184_CR84","unstructured":"Study Details (2026). | NCT05308836 | Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05308836?cond=NCT05308836&rank=1&tab=study (accessed Jan. 27."},{"key":"11184_CR85","unstructured":"Taiwan\u2013Vietnam Cross-Border Collaboration Completes Phase I Clinical Trial of Stem Cell Therapy for Diabetes (accessed Jan. 27, 2026). Preliminary Results Demonstrate Favorable Safety and Tolerability-GWOXI Stem Cell. https:\/\/en.gwoxi.com.tw\/news-146.html"},{"key":"11184_CR86","unstructured":"Study Details (2026). | NCT05061030 | Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05061030?cond=NCT05061030&rank=1 (accessed Jan. 27."},{"key":"11184_CR87","doi-asserted-by":"publisher","unstructured":"Xin, Y., et al. (Jan. 2016). Insulin-Producing Cells Differentiated from Human Bone Marrow Mesenchymal Stem Cells In Vitro Ameliorate Streptozotocin-Induced Diabetic Hyperglycemia. PLoS One, 11(1), e0145838. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0145838","DOI":"10.1371\/JOURNAL.PONE.0145838"},{"key":"11184_CR88","doi-asserted-by":"publisher","unstructured":"Kassem, D. H., Habib, S. A., Badr, O. I., & Kamal, M. M. (2022). Isolation of Rat Adipose Tissue Mesenchymal Stem Cells for Differentiation into Insulin-producing Cells, J. Vis. Exp., vol. no. 186, Aug. 2022. https:\/\/doi.org\/10.3791\/63348.","DOI":"10.3791\/63348"},{"key":"11184_CR89","doi-asserted-by":"publisher","unstructured":"Soleimanifar, F., et al. (Jun. 2024). The generation of islet-like insulin-producing cells from Wharton\u2019s jelly-derived mesenchymal stem cells on the PES\/fish gelatin scaffold. Regen Ther, 26, 251. https:\/\/doi.org\/10.1016\/J.RETH.2024.05.019","DOI":"10.1016\/J.RETH.2024.05.019"},{"key":"11184_CR90","doi-asserted-by":"publisher","unstructured":"Xu, B., et al. (Jan. 2020). Three-dimensional culture promotes the differentiation of human dental pulp mesenchymal stem cells into insulin-producing cells for improving the diabetes therapy. Frontiers In Pharmacology, 10, 509287. https:\/\/doi.org\/10.3389\/FPHAR.2019.01576\/BIBTEX","DOI":"10.3389\/FPHAR.2019.01576\/BIBTEX"},{"key":"11184_CR91","doi-asserted-by":"publisher","unstructured":"Mu, X. P., et al. (Jan. 2017). Enhanced differentiation of human amniotic fluid-derived stem cells into insulin-producing cells in vitro. J Diabetes Investig, 8(1), 34\u201343. https:\/\/doi.org\/10.1111\/JDI.12544","DOI":"10.1111\/JDI.12544"},{"key":"11184_CR92","doi-asserted-by":"publisher","unstructured":"Park, Y. M., Yang, C. M., & Cho, H. Y. (2022). Therapeutic Effects of Insulin-Producing Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Type 1 Diabetes Mouse Model, Int. J. Mol. Sci. Vol. 23, Page 6877, vol. 23, no. 13, p. 6877, Jun. 2022. https:\/\/doi.org\/10.3390\/IJMS23136877","DOI":"10.3390\/IJMS23136877"},{"key":"11184_CR93","doi-asserted-by":"publisher","unstructured":"Moriyama, H., Moriyama, M., Ozawa, T., Tsuruta, D., & Hayakawa, T. (2022). Differentiation of Human Adipose-Derived Mesenchymal Stromal\/Stem Cells into Insulin-Producing Cells with A Single Tet-Off Lentiviral Vector System, Cell J., vol. 24, no. 12, p. 705, Oct. https:\/\/doi.org\/10.22074\/CELLJ.2022.557533.1063","DOI":"10.22074\/CELLJ.2022.557533.1063"},{"key":"11184_CR94","doi-asserted-by":"publisher","unstructured":"Gao, D., Dai, P., Fan, Z., Wang, J., & Zhang, Y. (Mar. 2022). The Roles of Different Multigene Combinations of Pdx1, Ngn3, Sox9, Pax4, and Nkx2.2 in the Reprogramming of Canine ADSCs Into IPCs. Cell Transplantation, 31. https:\/\/doi.org\/10.1177\/09636897221081483\/SUPPL_FILE\/SJ-TIF-4-CLL-10.1177_09636897221081483.TIF","DOI":"10.1177\/09636897221081483\/SUPPL_FILE\/SJ-TIF-4-CLL-10.1177_09636897221081483.TIF"},{"key":"11184_CR95","doi-asserted-by":"publisher","unstructured":"Alzhanuly, B. (2021). Oct., Modulation of Insulin Gene Expression with CRISPR\/Cas9-based Transcription Factors, Open Access Maced. J. Med. Sci., vol. 9, no. A, pp. 876\u2013881. https:\/\/doi.org\/10.3889\/OAMJMS.2021.6980","DOI":"10.3889\/OAMJMS.2021.6980"},{"key":"11184_CR96","doi-asserted-by":"publisher","unstructured":"Li, Y., et al. (Aug. 2024). Engineered IRES-mediated promoter-free insulin-producing cells reverse hyperglycemia. Front Endocrinol (Lausanne), 15, 1439351. https:\/\/doi.org\/10.3389\/FENDO.2024.1439351\/BIBTEX","DOI":"10.3389\/FENDO.2024.1439351\/BIBTEX"},{"key":"11184_CR97","doi-asserted-by":"publisher","unstructured":"Dai, P., et al. (Dec. 2024). Knockout of B2M in combination with PD-L1 overexpression protects MSC-derived new islet \u03b2 cells from graft rejection in the treatment of canine diabetes mellitus. Stem Cell Research & Therapy, 15(1), 1\u201320. https:\/\/doi.org\/10.1186\/S13287-024-04067-7\/FIGURES\/9","DOI":"10.1186\/S13287-024-04067-7\/FIGURES\/9"},{"key":"11184_CR98","doi-asserted-by":"publisher","unstructured":"Long, A. E., George, G., & Williams, C. L. (Dec. 2021). Persistence of islet autoantibodies after diagnosis in type 1 diabetes. Diabetic Medicine, 38(12). https:\/\/doi.org\/10.1111\/dme.14712","DOI":"10.1111\/dme.14712"},{"key":"11184_CR99","doi-asserted-by":"publisher","unstructured":"Tokuda, K., et al. (Dec. 2022). Syngeneically transplanted insulin producing cells differentiated from adipose derived stem cells undergo delayed damage by autoimmune responses in NOD mice. Scientific Reports, 12(1), 5852. https:\/\/doi.org\/10.1038\/s41598-022-09838-x","DOI":"10.1038\/s41598-022-09838-x"},{"key":"11184_CR100","doi-asserted-by":"publisher","unstructured":"Van Megen, K. M., Van \u2019t Wout, E. J. T., Motta, J. L., Dekker, B., Nikolic, T., & Roep, B. O. (2019). Activated mesenchymal stromal cells process and present antigens regulating adaptive immunity, Front. Immunol., vol. 10, no. APR, p. 694. https:\/\/doi.org\/10.3389\/fimmu.2019.00694","DOI":"10.3389\/fimmu.2019.00694"},{"key":"11184_CR101","doi-asserted-by":"publisher","unstructured":"Fazeli, P., et al. (Mar. 2025). The role of memory T cells in type 1 diabetes: Phenotypes, mechanisms, and therapeutic implications. Autoimmun Rev, 24(4), 103759. https:\/\/doi.org\/10.1016\/J.AUTREV.2025.103759","DOI":"10.1016\/J.AUTREV.2025.103759"},{"key":"11184_CR102","unstructured":"Sana Biotechnology Announces Continued Positive Clinical Results Through (accessed May 20, 2026). 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Sana Biotechnology, Inc. https:\/\/ir.sana.com\/news-releases\/news-release-details\/sana-biotechnology-announces-continued-positive-clinical-results\/"},{"issue":"2","key":"11184_CR103","doi-asserted-by":"publisher","first-page":"184","DOI":"10.15283\/IJSC17028","volume":"10","author":"G Hassan","year":"2017","unstructured":"Hassan, G., Kasem, I., Soukkarieh, C., & Aljamali, M. (2017). A Simple Method to Isolate and Expand Human Umbilical Cord Derived Mesenchymal Stem Cells: Using Explant Method and Umbilical Cord Blood Serum. Int J Stem Cells, 10(2), 184. https:\/\/doi.org\/10.15283\/IJSC17028","journal-title":"Int J Stem Cells"},{"issue":"1","key":"11184_CR104","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5483\/BMBRep.2023-0113","volume":"57","author":"AR Han","year":"2024","unstructured":"Han, A. R., et al. (2024). Highly efficient genome editing via CRISPR-Cas9 ribonucleoprotein (RNP) delivery in mesenchymal stem cells. Bmb Reports, 57(1), 60. https:\/\/doi.org\/10.5483\/BMBRep.2023-0113","journal-title":"Bmb Reports"},{"key":"11184_CR105","doi-asserted-by":"publisher","unstructured":"Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (Jan. 2019). Viral Delivery Systems for CRISPR. Viruses, 11(1), 28. https:\/\/doi.org\/10.3390\/v11010028","DOI":"10.3390\/v11010028"},{"key":"11184_CR106","doi-asserted-by":"publisher","unstructured":"Chao, K. C., Chao, K. F., Fu, Y. S., & Liu, S. H. (Jan. 2008). Islet-Like Clusters Derived from Mesenchymal Stem Cells in Wharton\u2019s Jelly of the Human Umbilical Cord for Transplantation to Control Type 1 Diabetes. PLoS One, 3(1), e1451. https:\/\/doi.org\/10.1371\/journal.pone.0001451","DOI":"10.1371\/journal.pone.0001451"},{"key":"11184_CR107","doi-asserted-by":"publisher","unstructured":"Yang, X. F., Chen, T., Ren, L. W., Yang, L., Qi, H., & Li, F. R. (Apr. 2017). Immunogenicity of insulin-producing cells derived from human umbilical cord mesenchymal stem cells. Experimental and Therapeutic Medicine, 13(4), 1456. https:\/\/doi.org\/10.3892\/ETM.2017.4096","DOI":"10.3892\/ETM.2017.4096"},{"key":"11184_CR108","doi-asserted-by":"publisher","unstructured":"Abazari, M. F., et al. (May 2020). Comparison of human-induced pluripotent stem cells and mesenchymal stem cell differentiation potential to insulin producing cells in 2D and 3D culture systems in vitro. Journal Of Cellular Physiology, 235(5), 4239\u20134246. https:\/\/doi.org\/10.1002\/jcp.29298","DOI":"10.1002\/jcp.29298"},{"key":"11184_CR109","doi-asserted-by":"publisher","unstructured":"Silva, I. B. B., Kimura, C. H., Colantoni, V. P., & Sogayar, M. C. (2022 131). Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges. Stem Cell Research & Therapy, 13(1), 309. https:\/\/doi.org\/10.1186\/s13287-022-02977-y","DOI":"10.1186\/s13287-022-02977-y"},{"key":"11184_CR110","unstructured":"Wang, Q., Ye, L., Liu, H., Liu, X., Li, S., & Chen, Z. (2012). Reprogramming of bone marrow-derived mesenchymal stem cells into functional insulin-producing cells by chemical regimen. American Journal of Stem Cells, 1(2), 128. Available: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3636740\/.\u00a0Accessed 19 Feb 2026."},{"key":"11184_CR111","doi-asserted-by":"publisher","unstructured":"Gheibi, S., Singh, T., da Cunha, J. P. M. C. M., Fex, M., & Mulder, H. (Nov. 2020). Insulin\/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes. Cells, 9(11), 2465. https:\/\/doi.org\/10.3390\/cells9112465","DOI":"10.3390\/cells9112465"},{"key":"11184_CR112","doi-asserted-by":"publisher","unstructured":"Arroyave, F., Usc\u00e1tegui, Y., & Lizcano, F. (Sep. 2024). From iPSCs to Pancreatic \u03b2 Cells: Unveiling Molecular Pathways and Enhancements with Vitamin C and Retinoic Acid in Diabetes Research. International Journal Of Molecular Sciences, 25(17), 9654. https:\/\/doi.org\/10.3390\/ijms25179654","DOI":"10.3390\/ijms25179654"},{"key":"11184_CR113","doi-asserted-by":"publisher","unstructured":"Huang, Q., Huang, Y., & Liu, J. (2021). Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus. International journal of endocrinology, 2021, 9938658. https:\/\/doi.org\/10.1155\/2021\/9938658","DOI":"10.1155\/2021\/9938658"},{"key":"11184_CR114","doi-asserted-by":"publisher","unstructured":"Czubak, P., Bojarska-Junak, A., Tabarkiewicz, J., & Putowski, L. (2014). A modified method of insulin producing cells\u2019 generation from bone marrow-derived mesenchymal stem cells. Journal of diabetes research, 2014, 628591. https:\/\/doi.org\/10.1155\/2014\/628591","DOI":"10.1155\/2014\/628591"},{"key":"11184_CR115","unstructured":"Gabr, M., Ismail, A., & Refaie, A. (2011). Differentiation of Rat Bone Marrow-Derived Mesenchymal Stem Cells into Insulin-Producing Cells."},{"key":"11184_CR116","doi-asserted-by":"publisher","unstructured":"Thorngren, J., et al. (Feb. 2024). Differentiation of human pluripotent stem cells into insulin-producing islet-like clusters using nanofiltered cell culture medium. Frontier Membranes Science Technology, 3, 1338366. https:\/\/doi.org\/10.3389\/frmst.2024.1338366","DOI":"10.3389\/frmst.2024.1338366"},{"key":"11184_CR117","doi-asserted-by":"publisher","unstructured":"Balboa, D. (2022 407). Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nature biotechnology, 40(7), 1042\u20131055. https:\/\/doi.org\/10.1038\/s41587-022-01219-z","DOI":"10.1038\/s41587-022-01219-z"},{"key":"11184_CR118","doi-asserted-by":"publisher","unstructured":"Kumar, D., & Tanwar, R. (Dec. 2024). World\u2019s first: stem cell therapy reverses diabetes. Stem Cell Research & Therapy, 15(1), 487. https:\/\/doi.org\/10.1186\/s13287-024-04036-0","DOI":"10.1186\/s13287-024-04036-0"},{"key":"11184_CR119","doi-asserted-by":"publisher","unstructured":"Liu, X., Li, W., Fu, X., & Xu, Y. (2017). The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Frontiers in Immunology, 8, 270365. https:\/\/doi.org\/10.3389\/fimmu.2017.00645","DOI":"10.3389\/fimmu.2017.00645"},{"key":"11184_CR120","doi-asserted-by":"publisher","unstructured":"Upadhye, K. S., & Tayade, P. (Feb. 2026). Advances in stem cell\u2013derived beta-cell therapy: A new frontier in type 1 diabetes treatment. Cell Transplantation, 35, 09636897261417623. https:\/\/doi.org\/10.1177\/09636897261417623","DOI":"10.1177\/09636897261417623"},{"key":"11184_CR121","doi-asserted-by":"publisher","unstructured":"Reichman, T. W. (2025). Sep., Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. The New England journal of medicine, 393(9), 858\u2013868. https:\/\/doi.org\/10.1056\/NEJMOA2506549","DOI":"10.1056\/NEJMOA2506549"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11184-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11184-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:58:58Z","timestamp":1788764338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11184-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":121,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11184"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11184-8","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}